380 related articles for article (PubMed ID: 25009231)
1. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.
Rebouissou S; Bernard-Pierrot I; de Reyniès A; Lepage ML; Krucker C; Chapeaublanc E; Hérault A; Kamoun A; Caillault A; Letouzé E; Elarouci N; Neuzillet Y; Denoux Y; Molinié V; Vordos D; Laplanche A; Maillé P; Soyeux P; Ofualuka K; Reyal F; Biton A; Sibony M; Paoletti X; Southgate J; Benhamou S; Lebret T; Allory Y; Radvanyi F
Sci Transl Med; 2014 Jul; 6(244):244ra91. PubMed ID: 25009231
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
3. Bladder cancers respond to EGFR inhibitors.
Cancer Discov; 2014 Sep; 4(9):980-1. PubMed ID: 25185172
[TBL] [Abstract][Full Text] [Related]
4. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
[TBL] [Abstract][Full Text] [Related]
5. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
6. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.
Zheng Y; Izumi K; Yao JL; Miyamoto H
Endocr Relat Cancer; 2011 Aug; 18(4):451-64. PubMed ID: 21613411
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells.
Black PC; Brown GA; Inamoto T; Shrader M; Arora A; Siefker-Radtke AO; Adam L; Theodorescu D; Wu X; Munsell MF; Bar-Eli M; McConkey DJ; Dinney CP
Clin Cancer Res; 2008 Mar; 14(5):1478-86. PubMed ID: 18316572
[TBL] [Abstract][Full Text] [Related]
8. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
9. Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment.
Kiselyov A; Bunimovich-Mendrazitsky S; Startsev V
Int J Cancer; 2016 Jun; 138(11):2562-9. PubMed ID: 26547270
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers.
Lubet RA; Lu Y; Bode AM; You M; Verney ZM; Steele VE; Townsend R; Juliana MM; Grubbs CJ
Oncol Rep; 2011 May; 25(5):1389-97. PubMed ID: 21369704
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder.
Wang X; Zhang S; MacLennan GT; Eble JN; Lopez-Beltran A; Yang XJ; Pan CX; Zhou H; Montironi R; Cheng L
Clin Cancer Res; 2007 Feb; 13(3):953-7. PubMed ID: 17289890
[TBL] [Abstract][Full Text] [Related]
12. Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.
Chang N; Lee HW; Lim JE; Jeong DE; Song HJ; Kim S; Nam DH; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
Oncotarget; 2016 Aug; 7(32):51626-51639. PubMed ID: 27438149
[TBL] [Abstract][Full Text] [Related]
13. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
Kawashima A; Nakayama M; Kakuta Y; Abe T; Hatano K; Mukai M; Nagahara A; Nakai Y; Oka D; Takayama H; Yoshioka T; Hoshida Y; Itatani H; Nishimura K; Nonomura N
Clin Cancer Res; 2011 Apr; 17(8):2561-9. PubMed ID: 21177407
[TBL] [Abstract][Full Text] [Related]
14. Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer.
Black PC; Brown GA; Dinney CP; Kassouf W; Inamoto T; Arora A; Gallagher D; Munsell MF; Bar-Eli M; McConkey DJ; Adam L
J Urol; 2011 Feb; 185(2):693-700. PubMed ID: 21168861
[TBL] [Abstract][Full Text] [Related]
15. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
[TBL] [Abstract][Full Text] [Related]
16. Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer.
Lu Y; Liu P; Van den Bergh F; Zellmer V; James M; Wen W; Grubbs CJ; Lubet RA; You M
Cancer Prev Res (Phila); 2012 Feb; 5(2):248-59. PubMed ID: 21982874
[TBL] [Abstract][Full Text] [Related]
17. Activation of PPARγ and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells.
Mehus AA; Bergum N; Knutson P; Shrestha S; Zhou XD; Garrett SH; Sens DA; Sens MA; Somji S
PLoS One; 2020; 15(8):e0237976. PubMed ID: 32822399
[TBL] [Abstract][Full Text] [Related]
18. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
[TBL] [Abstract][Full Text] [Related]
19. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
[TBL] [Abstract][Full Text] [Related]
20. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
